Our study provides biological and clinical rationale for additional preclinical testing of USP7 inhibitors in children with high-risk and relapsed NB and emphasizes the need for further research to characterize USP7′s various targets and understand the roles they play in NB tumor development and growth. This evidence concerns the gene USP7 and neuroblastoma.